Scarica l'app Stockscreener
0.9323
2.24%
0.0204
Ironwood Pharmaceuticals Inc Borsa (IRWD) Ultime notizie
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Ironwood Pharmaceuticals to Participate in The Citizens Life Sci - GuruFocus
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference - Business Wire
Press Release Distribution & PR Platform - ACCESS Newswire
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025 - GuruFocus
Ironwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock News - GuruFocus
Ironwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares rise - MSN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance - ADVFN
Ironwood Pharmaceuticals Reiterates Full-Year 2025 Guidance and Raises Adjusted EBITDA - TradingView
Ironwood Pharmaceuticals to Present Real-World Data at Digestive - GuruFocus
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support - itemonline.com
Ironwood looks for strategic options after regulatory hurdle for lead drug - MSN
Ironwood Pharmaceuticals to Explore Strategic Alternatives to Maximize Value for Stockholders - marketscreener.com
Why Ironwood Pharmaceuticals Inc. (IRWD) Went Down On Thursday? - MSN
Ironwood Shares Tank on Regulatory Update for Apraglutide - MSN
Ironwood Pharmaceuticals (IRWD) Faces Setback After FDA Request - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges A - GuruFocus
Ironwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges Amid FDA Trial Delay | IRWD Stock News - GuruFocus
Ironwood downgraded at Jefferies on apraglutide-related challenges - MSN
Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) - MSN
Ironwood downgraded at Jefferies on apraglutide-related challenges (IRWD:NASDAQ) - Seeking Alpha
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7 - marketscreener.com
Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8 - marketscreener.com
Ironwood crashes down as FDA seeks new phase 3 trial - Pharmaphorum
Ironwood (IRWD) Shares Downgraded by Jefferies Following FDA Set - GuruFocus
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock News - GuruFocus
Ironwood (IRWD) Plummets After Downgrade and FDA Trial Delay | I - GuruFocus
Ironwood To Consider All Options With Apraglutide Setback In SBS - insights.citeline.com
Ironwood's Strategy Shake-Up Raises Eyebrows As Shares Tumble - Finimize
Ironwood requires new trial for SBS drug approval By Investing.com - Investing.com South Africa
Top Midday Decliners - MarketScreener
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug - Benzinga
Ironwood to considers merger opportunities after FDA setback - The Business Journals
Crude Oil Moves Lower; M&T Bank Earnings Miss Views - Benzinga
Ironwood (IRWD) Faces Financial Uncertainty as Price Target is S - GuruFocus
Ironwood (IRWD) Faces Financial Uncertainty as Price Target is Slashed | IRWD Stock News - GuruFocus
Ironwood: FDA nay on PK means another apraglutide study - BioWorld MedTech
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide - BioSpace
Ironwood Pharma Shares Fall on Word of Confirmatory Phase 3 Apraglutide Trial - MarketWatch
Ironwood Pharmaceuticals (IRWD) Considers Strategic Options Afte - GuruFocus
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals stock tumbles after FDA requires additional trial - Investing.com Australia
Nasdaq Surges 2%; Goldman Sachs Posts Upbeat Earnings - Benzinga
Ironwood Says FDA to Require Additional Phase 3 Trial for Apraglutide; to Explore Strategic Options - MarketScreener
Ironwood Pharma stock down on regulatory hurdle (IRWD:NASDAQ) - Seeking Alpha
Ironwood Pharma Provides Update On Apraglutide; Plans Strategic Alternatives - Nasdaq
Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Followin - GuruFocus
Ironwood requires new trial for SBS drug approval - Investing.com
Ironwood (IRWD) Plans New Phase 3 Trial for Apraglutide Following FDA Talks | IRWD Stock News - GuruFocus
Ironwood's Apraglutide Faces FDA Setback: Strategic Review Launched After Trial Issues - Stock Titan
3.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):